NasdaqGS:QUREBiotechs
Why uniQure (QURE) Is Down 12.0% After AMT-130 Lawsuits Challenge Its FDA Milestone Story
In early February 2026, multiple law firms filed securities fraud class action lawsuits against uniQure N.V., alleging that the company misled investors about U.S. FDA alignment, pivotal study design, and the likelihood of accelerated approval for its Huntington’s disease gene therapy candidate, AMT-130, during late 2025.
At the same time, uniQure reported new Phase I/IIa data on its Fabry disease program AMT-191, underscoring a broader pipeline but also highlighting clinical and safety...